Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
出版年份 2016 全文链接
标题
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
作者
关键词
-
出版物
ACTA PHARMACOLOGICA SINICA
Volume 37, Issue 7, Pages 930-940
出版商
Springer Nature
发表日期
2016-05-16
DOI
10.1038/aps.2016.55
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
- (2014) Chieh-Chien Lee et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Modeling NSCLC Progression: Recent Advances and Opportunities Available
- (2013) Ahmed Abbas Suleiman et al. AAPS Journal
- Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and Gemcitabine
- (2013) Mengyao Li et al. PHARMACEUTICAL RESEARCH
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study
- (2012) George R. Blumenschein et al. Journal of Thoracic Oncology
- EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
- (2011) V. Poindessous et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
- (2010) L. Salphati et al. DRUG METABOLISM AND DISPOSITION
- Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
- (2009) Joshua Ö. Haznedar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
- (2009) G. N. Naumov et al. CLINICAL CANCER RESEARCH
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
- (2009) Y Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Modeling of tumor growth and anticancer effects of combination therapy
- (2009) Gilbert Koch et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients
- (2008) L.-S. Tham et al. CLINICAL CANCER RESEARCH
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
- (2008) Giampaolo Tortora et al. Nature clinical practice. Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started